Lyell Immunopharma, Inc. Deferred Tax Assets, Goodwill and Intangible Assets
Lyell Immunopharma, Inc. (LYEL) had Deferred Tax Assets, Goodwill and Intangible Assets of $30.11 million as of 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets · last filed 2026-03-12
- 2025-12-31: Deferred Tax Assets, Goodwill and Intangible Assets $30.11M.
- 2024-12-31: Deferred Tax Assets, Goodwill and Intangible Assets $5.58M.
- 2023-12-31: Deferred Tax Assets, Goodwill and Intangible Assets $5.24M.
- 2022-12-31: Deferred Tax Assets, Goodwill and Intangible Assets $4.58M.
| Period end | Deferred Tax Assets, Goodwill and Intangible Assets |
|---|---|
| 2025-12-31 | $30.11M 10-K · filed 2026-03-12 |
| 2024-12-31 | $5.58M 10-K · filed 2026-03-12 |
| 2023-12-31 | $5.24M 10-K · filed 2025-03-11 |
| 2022-12-31 | $4.58M 10-K · filed 2024-02-28 |
| 2021-12-31 | $15.96M 10-K · filed 2023-02-28 |
| 2020-12-31 | $14.38M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |